Skip to content

The influence of tegileridine fumarate injection on postoperative inflammatory response and gastrointestinal function in patients undergoing laparoscopic cholecystectomy

The influence of tegileridine fumarate injection on postoperative inflammatory response and gastrointestinal function in patients undergoing laparoscopic cholecystectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111151
Enrollment
Unknown
Registered
2025-10-27
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallbladder disorders

Interventions

Experimental group(T group):Administration of Tegileridine Fumarate for postoperative analgesia
Control group(C group):Inject the same volume of normal saline

Sponsors

Jingmen People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18–65 years; 2. Laparoscopic cholecystectomy under general anesthesia; 3. No history of drug allergies; 4. Complete clinical data; 5. ASA classification: I–II (American Society of Anesthesiologists classification, indicating good physical condition); 6. Informed consent: patients voluntarily participate in the study and sign an informed consent form; 7. No serious underlying diseases: such as normal heart, lung, liver, and kidney function; 8. This study protocol has been approved by the hospital's medical ethics committee, and patients have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe systemic diseases: such as severe cardiovascular diseases, liver and kidney dysfunction, immune system disorders, etc.; 2. Pregnant or breastfeeding women: to avoid potential effects of drugs on the fetus or infant; 3. Long-term use of anti-inflammatory or analgesic drugs: such as non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, etc.; 4. Recent infection or inflammation: patients with clear infection or inflammation before surgery (e.g., acute episode of cholecystitis); 5. Mental illness or cognitive impairment: unable to cooperate with the study or report postoperative symptoms; 6. Intraoperative conversion to open surgery, with unstable vital signs.

Design outcomes

Primary

MeasureTime frame
Serum white blood cell count;procalcitonin;C-reactive protein;interleukin-6;tumor necrosis factor a;Postoperative gastrointestinal function;

Secondary

MeasureTime frame
VAS scores at rest and during activity after the operation;15-item Quality of Recovery Scale ;The incidence of postoperative adverse reactions;

Countries

China

Contacts

Public ContactZhou Xing

Jingmen People's Hospital

690034393@qq.com+86 138 7291 4671

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026